Literature DB >> 11771749

Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease.

S H Kim1, A C Nairn, N Cairns, G Lubec.   

Abstract

ARPP-19 (cAMP-regulated phosphoprotein of Mr = 19,000) is a substrate for cAMP-dependent protein kinase (PKA). ARPP-19 is found in all brain regions but the function of ARPP-19 is not fully elucidated yet. We detected a downregulated sequence with 100% homology with ARPP-19 in temporal cortex of patients with Down syndrome (DS) as compared to controls, but not in Alzheimer's disease (AD) using differential displaypolymerase chain reaction (DD-PCR). We subsequently determined protein levels of ARPP-19 in temporal cortex and cerebellum by immunoblotting and observed significant reduction of ARPP-19 in DS (temporal cortex) and AD (cerebellum). We also observed decreased activities of PKA in DS (temporal cortex and cerebellum) and AD (temporal cortex). These findings suggest that decreased ARPP-19 along with decreased activities of PKA is involved in pathomechanisms of both neurodegenerative disorders. Furthermore, these findings provide first evidence for an impaired mechanism of cAMP-related signal transduction and phosphorylation in both dementing disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771749     DOI: 10.1007/978-3-7091-6262-0_21

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  25 in total

Review 1.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 2.  cAMP regulation of protein phosphatases PP1 and PP2A in brain.

Authors:  Shannon N Leslie; Angus C Nairn
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-18       Impact factor: 4.739

3.  Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Jun-Ting Yang; Zhao-Jun Wang; Hong-Yan Cai; Li Yuan; Meng-Ming Hu; Mei-Na Wu; Jin-Shun Qi
Journal:  Neurosci Bull       Date:  2018-08-11       Impact factor: 5.203

Review 4.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 5.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

Review 6.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

Review 7.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  The role of cerebellar genes in pathology of autism and schizophrenia.

Authors:  S Hossein Fatemi; Teri J Reutiman; Timothy D Folsom; Robert W Sidwell
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 9.  Signal transduction therapeutics: relevance for Alzheimer's disease.

Authors:  Odete A B da Cruz e Silva; Margarida Fardilha; Ana Gabriela Henriques; Sandra Rebelo; Sandra Vieira; Edgar F da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain.

Authors:  Zhihou Liang; Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2007-10-01       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.